Pages that link to "Q41530531"
Jump to navigation
Jump to search
The following pages link to Once-daily dosing of aminoglycosides: review and recommendations for clinical practice (Q41530531):
Displaying 50 items.
- Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit (Q28950856) (← links)
- Pharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature Review (Q29248398) (← links)
- Applications of flow cytometry to clinical microbiology (Q33555394) (← links)
- Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference (Q33640559) (← links)
- Antimicrobial agents. (Q33660827) (← links)
- Therapeutic drug monitoring of amikacin in septic patients. (Q33754166) (← links)
- Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment (Q33824149) (← links)
- Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children (Q34106577) (← links)
- A multicenter evaluation of gentamicin therapy in the neonatal intensive care unit (Q34146978) (← links)
- Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside (Q34443415) (← links)
- Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations (Q34476089) (← links)
- Accuracy of empiric gentamicin dosing guidelines in neonates (Q34589031) (← links)
- Risk factors for toxicity in elderly patients given aminoglycosides once daily. (Q34752229) (← links)
- Once-daily aminoglycosides in patients with neutropenic fever (Q34985783) (← links)
- Clinical issues surrounding once-daily aminoglycoside dosing in children (Q35043373) (← links)
- Management of infection in children with malignancy (Q35082359) (← links)
- Tobramycin exposure from active calcium sulfate bone graft substitute (Q35110405) (← links)
- Versatility of aminoglycosides and prospects for their future (Q35176271) (← links)
- Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. (Q35262273) (← links)
- New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms (Q35616211) (← links)
- New developments in antibacterial choice for lower respiratory tract infections in elderly patients (Q35673808) (← links)
- Once-daily aminoglycoside dosing: An update on current literature (Q35738386) (← links)
- Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis (Q35745888) (← links)
- Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing (Q35806154) (← links)
- Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. (Q35826231) (← links)
- Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs (Q35826457) (← links)
- Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem (Q35914401) (← links)
- Optimization of antibiotic dosing schedules in the light of increasing antibiotic resistance (Q35917371) (← links)
- Studying outcomes of intensive care unit survivors: measuring exposures and outcomes. (Q36134900) (← links)
- Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance (Q36247318) (← links)
- Continuous beta-lactam infusion in critically ill patients: the clinical evidence (Q36329228) (← links)
- Providing guidelines and education is not enough: an audit of gentamicin use at The Royal Melbourne Hospital (Q36366980) (← links)
- Pharmacodynamics of antimicrobials: treatment optimisation (Q36544935) (← links)
- Treatment of Pseudomonas aeruginosa infection in critically ill patients (Q36607415) (← links)
- Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature (Q36739797) (← links)
- Atorvastatin for Prevention of Amikacin-induced Electrolytes Imbalances; a Randomized Clinical Trial (Q37246422) (← links)
- Pharmacokinetic and pharmacodynamic properties of meropenem (Q37247125) (← links)
- Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients (Q37265496) (← links)
- High-Dose, Extended-Interval Gentamicin and Tobramycin for Pediatric Inpatients: A Survey of Canadian Hospital Pharmacists (Q37376795) (← links)
- Pharmacist-driven aminoglycoside quality improvement program (Q37417871) (← links)
- Appropriate use of antimicrobials: the peculiarity of septic patients (Q37636910) (← links)
- Pharmacotherapy of diabetic foot osteomyelitis. (Q37642761) (← links)
- Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis (Q37661512) (← links)
- Aminoglycoside therapy in infectious diseases (Q38112810) (← links)
- Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence (Q38147851) (← links)
- Aminoglycoside toxicity in neonates: something to worry about? (Q38181171) (← links)
- Aminoglycosides use in patients over 75 years old. (Q38192961) (← links)
- Antimicrobial agents, drug adverse reactions and interactions, and cancer (Q38202581) (← links)
- Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature (Q38239999) (← links)
- Aminoglycoside-induced nephrotoxicity (Q38246945) (← links)